Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and response to first-line erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p)

被引：0
|
作者：
Reguart-Aransay, Noemi [1 ]
Mayo, Clara [1 ]
Queralt, Cristina [1 ]
Botia, Monica [1 ]
Pastor, Carmen [1 ]
Perez, Maria [1 ]
Catot, Silvia [1 ]
Prada, Anna [1 ]
Galvez, Marc [1 ]
Taron, Miquel [1 ]
Rosell, Rafael [1 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, ICO, Barcelona, Spain
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1296
引用
收藏
页数：2
相关论文
共 50 条
  • [1] First-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, Bartomeu
    Reguart, Noemi
    Vivanco, Guillermo Lopez
    Provencio, Mariano
    Isla, Dolores
    Camps, Carlos
    Ares, Luis Paz
    Pradas, Anna
    Taron, Miquel
    Rosell, Rafael
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 216 - 216
  • [2] First-line erlotinib in stage IV non-small cell lung cancer (NSCLC) patients (pts) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, B.
    Porta, R.
    Paz-Ares, L.
    Cardenal, F.
    Lopez-Vivanco, G.
    Provencio, M.
    Isla, D.
    Pradas, A.
    Taron, M.
    Rosell, R.
    [J]. LUNG CANCER, 2006, 52 : S25 - S26
  • [3] A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR).
    Paz-Ares, L.
    Sanchez, J. M.
    Garcia-Velasco, A.
    Massuti, B.
    Lopez-Vivanco, G.
    Provencio, M.
    Montes, A.
    Isla, D.
    Amador, M. L.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 369S - 369S
  • [4] Epidermal growth factor receptor (EGFR) activating mutations (muts) in the tyrosine kinase (TK) domain correlate with gefitinib response in chemorefractory non-small-cell lung cancer (NSCLC).
    Taron, M
    Ichinose, Y
    Rosell, R
    Mok, T
    Massuti, B
    Manegold, C
    Queralt, C
    Jahan, T
    Hsue, V
    Jablons, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 642S - 642S
  • [5] Deciding on second- or third-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) based on the presence of mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Porta, Rut
    Terrasa, Josefa
    Rolfo, Cristian
    Gonzalez Larriba, Jose Luis
    Garcia Campelo, Rosario
    Mesia, Carlos
    Pallares, Cinta
    Lianes, Pilar
    Queralt, Cristina
    Rosell, Rafael
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 215 - 216
  • [6] Response to first-line chemotherapy and sensitivity to epidermal growth factor receptor (EGFR) inhibitors in advanced non-small-cell lung cancer (NSCLC) patients
    Betti, Maura
    Toschi, L.
    Metro, G.
    Bartolini, Stefania
    Magrini, E.
    de Angelis, Verena
    Chiari, Rita
    Ferraldeschi, Massimiliano
    Cappuzzo, Federico
    Crino, Lucio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [7] Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
    Cardenal, Felipe
    Moran, Teresa
    Queralt, Cristina
    Porta, Ruth
    Camps, Carlos
    Majem, Margarita
    Lopez-Vivanco, Guillermo
    Isla, Dolores
    Provencio, Mariano
    Sanchez, Jose Javier
    Taron, Miquel
    Rosell, Rafael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S324 - S325
  • [8] Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut plus )
    Petruzelka, Lubos
    [J]. LUNG CANCER, 2012, 77 : S25 - S25
  • [9] Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
    Porta, R.
    Queralt, C.
    Cardenal, F.
    Mayo, C.
    Provencio, M.
    Camps, C.
    Isla, D.
    Gonzalez-Larriba, J.
    Taron, M.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer
    Nishio, Makoto
    Goto, Koichi
    Chikamori, Kenichi
    Hida, Toyoaki
    Katakami, Nobuyuki
    Maemondo, Makoto
    Ohishi, Norihisa
    Tamura, Tomohide
    [J]. CLINICAL LUNG CANCER, 2016, 17 (01) : 24 - +
12345